Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
Authors:
Open Access
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Current approaches to the management of brain metastasesNature Reviews Clinical Oncology, 2020
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2020
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain MetastasesJournal of Clinical Oncology, 2019
- Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)Clinical Cancer Research, 2017
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAAnnals of Oncology, 2014
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2013
- CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)The Lancet Oncology, 2013
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer TissuesClinical Breast Cancer, 2004
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003